Psilocybin and Longevity: What the 2025 Research Actually Showed

A Study That Caught Attention

On July 8, 2025, a study appeared in npj Aging that sparked considerable debate in scientific circles. Researchers at Emory University and Baylor College of Medicine, led by Dr. Louise Hecker and Dr. Kosuke Kato, had investigated something that hadn't received much attention until then: what does psilocybin – the active compound in magic mushrooms – actually do to aging at the cellular level?

The results? Cells lived up to 57% longer. Aging mice had 30% better survival odds. And while the study was immediately picked up by media worldwide, the scientific community was more cautious. Yes, the numbers were impressive. But they also raise questions.

We're now in early 2026, and there's been time to digest these findings. To look at what they do and don't mean. And to examine the methodology critically. Because that's what science is about – enthusiasm combined with healthy skepticism.

What Did They Actually Study?

The research team approached it in two phases. First, they looked at human fibroblasts – cells from lungs and skin – in a laboratory setting. They treated these cells with psilocin (the active metabolite of psilocybin) and tracked how long the cells kept dividing before becoming senescent. Senescent means cells stop dividing and enter a kind of resting state, often releasing inflammatory compounds that accelerate the aging process.

At a dosage of 10 micromolar psilocin, cells lived 29% longer. At higher dosages, that jumped to 57%. The treated cells showed fewer signs of cellular aging, had better-protected telomeres (the protective caps at the ends of DNA strands), and produced more SIRT1 – a protein that sits at the center of longevity research.

From Cell to Organism

Cellular studies are one thing, but does it work in living beings? That's why the researchers used female mice that were 19 months old – roughly comparable to humans aged 60-65. The mice received psilocybin once a month: 5 mg/kg the first time, then 15 mg/kg nine more times. Ten months of treatment in total.

The results: after ten months, 80% of the psilocybin group was still alive, compared to 50% of the control group. That's a 60% improvement in survival rate. What's more, the researchers saw visual improvements: better coat quality, fewer gray hairs, even hair regrowth in areas where it had previously disappeared.

The Mechanisms: What's Happening?

The researchers proposed that psilocybin triggers a cascade of cellular effects through serotonin receptors (specifically 5-HT2A). One of the central players is SIRT1, a protein involved in DNA repair, mitochondrial function, and stress response. SIRT1 activation has already been linked to lifespan extension in various organisms.

October 2025: The Critical View

Not everyone was equally enthusiastic. In October 2025, Dr. Peter Attia – a well-known longevity physician and scientist – published a detailed analysis pointing out methodological weaknesses. His main points? The study used a forced endpoint. As soon as 50% of the control mice had died, they stopped the experiment.

That means we don't know what the true median lifespan of the psilocybin group was. We also don't know whether psilocybin extended maximum lifespan – how old the longest-lived mice got. All we know is that more psilocybin mice made it to the endpoint. That's interesting, but it's not the same as proven lifespan extension.

Attia also pointed to the telomere hypothesis. While the study showed that psilocin protects telomeres, there's actually little evidence that telomere length reliably correlates with lifespan across species. Mice, for example, have much longer telomeres than humans but live only a fraction as long. Telomere length mainly reflects how many times a cell has divided, not necessarily biological age.

Nuance Matters

That doesn't take away from the fact that the findings are interesting. Because even if the telomere mechanism doesn't hold up, the study did see that more animals survived the experiment. And the cellular effects – reduced inflammation, better SIRT1 activation, lower oxidative stress – are all processes genuinely linked to healthy aging.

The researchers themselves were also cautious in their conclusions. Dr. Kato emphasized in interviews that much more research is needed: "We need to find optimal dosing protocols, understand at what age it's best to start, and especially figure out if there are long-term risks before this is ready for widespread use."

Early 2026: Where Do We Stand Now?

The study has at least created momentum. Multiple research groups have announced follow-up studies. They're looking at male mice (the original study used only females), different dosing protocols, and combinations with other longevity interventions like calorie restriction or certain supplements.

There's also interest from the pharmaceutical sector. Because if the effects hold up, we're not just talking about mushrooms as a recreational substance or even as a therapeutic for depression. We're talking about a compound that influences fundamental aging processes. That has health and economic value, and that attracts investment.

At the same time, big questions remain. The legal status of psilocybin in many countries makes research complicated and expensive. Long-term safety of regular use is unknown. And of course: what works in mice doesn't automatically work in humans. Human longevity studies by definition take decades, so we probably won't get quick answers.

Practical Consideration

For anyone thinking: should I start using psilocybin for anti-aging? The answer is: probably not, not yet. The data are promising but preliminary. We don't know enough about long-term effects, especially not in the context of regular use over multiple years.

What you can do is stay aware of this development. The longevity field is moving fast, and psychedelics are being assigned a new role beyond their traditional therapeutic use. The Netherlands, with its pragmatic policy around truffles, has an interesting position – there's room for responsible experimentation within legal frameworks.

But as with all longevity interventions: it's not a magic solution. The mice that responded best weren't just those with psilocybin, but probably also those with otherwise optimal living conditions. Exercise, nutrition, sleep, stress – those remain the foundations. Psilocybin might be a potential addition to that, but not a replacement.

The Bigger Picture

This study fits into a broader pattern. We're starting to see psychedelics differently. Not just as consciousness-altering substances or even just as medicines for mental health conditions, but as compounds that influence fundamental biological processes in ways that reach further than we thought.

Is psilocybin really the key to longer life? We'll only know in years, maybe decades. But what this study shows at minimum is that the question is worth asking. And that alone is interesting enough to keep following developments.

Sources

• Kato, K., Kleinhenz, J.M., Shin, Y.J., et al. (2025). Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging, 11(1):55.
• Emory University: Psilocybin delays aging, extends lifespan, new study suggests (July 10, 2025)
• Peter Attia, MD: A critical look at the lifespan-extending promise of psilocybin (October 27, 2025)